Sign in

CIK 0000822370 · Non-accelerated filer<br>Smaller reporting company

Emmaus Life Sciences, Inc.

Sign in to watch
Ticker
EMMA
Exchange
OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
870419387
Phone
310-214-0065
Business address
21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503
Former names
MYnd Analytics, Inc., CNS RESPONSE, INC., STRATIVATION, INC., SalesTactix, Inc., AGE RESEARCH INC
  1. 4 Open-market buy Chairman and CEO bought 9,500 shares at an average $1.53 ($14,570)
  2. 4 Open-market buy Chairman and CEO bought 6,600 shares at an average $1.58 ($10,456)
  3. 4 Open-market buy Chairman and CEO bought 4,400 shares at an average $1.53 ($6,752)
  4. 4 Open-market buy Chairman and CEO bought 41,350 shares at an average $1.54 ($63,646)
  5. SC 13D/A Stake Beneficial Ownership Report
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market buy Vice Chairman & COO bought 55,533 shares at an average $1.47 ($81,612)
  8. 4 Open-market buy Chairman and CEO bought 72,009 shares at an average $1.42 ($102,173)
  9. 8-K Event Executive or director change · Shareholder vote results
  10. 4 Open-market buy Chairman and CEO bought 26,300 shares at an average $1.34 ($35,312)
  11. 4 Open-market buy Vice Chairman & COO bought 38,000 shares at an average $1.34 ($50,850)
  12. 4 Open-market buy Vice Chairman & COO bought 18,600 shares at an average $1.38 ($25,649)
  13. 4 Open-market buy Chairman and CEO bought 27,000 shares at an average $1.41 ($38,130)
  14. 4 Open-market buy Chairman and CEO bought 33,000 shares at an average $1.28 ($42,310)
  15. 10-Q Report Quarterly Report
  16. 4 Open-market buy Chairman and CEO bought 1,000 shares at $1.57 ($1,570)
  17. DEF 14A Proxy Proxy Statement
  18. 8-K Event Material agreement
  19. 4 Open-market buy Chairman and CEO bought 3,000 shares at an average $1.61 ($4,840)
  20. PRE 14A Proxy Proxy Statement (Preliminary)

Page 8 of 63 · 1,250 filings